Perioperative Use of Erector Spinae Plane Block (ESPB) and Intravenous Lidocaine Infusion in Anesthetic Management of Spinal Surgery in Children
Launched by SAINT PETERSBURG STATE UNIVERSITY, RUSSIA · May 2, 2025
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two methods of pain relief for children who are having spinal surgery. The researchers want to find out if using a specific type of regional anesthesia called the Erector Spinae Plane Block (ESPB) can help children feel less pain after surgery compared to an intravenous (IV) lidocaine infusion, which is a medication given through a vein. The goal is to see if the ESPB can keep children comfortable longer before they need additional pain management.
Children between the ages of 3 and 17 who are scheduled for elective surgery on the thoracic (mid-back) or lumbosacral (lower back) spine may be eligible to participate in this study. To join, parents must provide signed consent, and the child must not have any medical conditions that would prevent the use of local anesthetics or require surgery on the cervical (neck) spine. During the trial, participants will receive either the ESPB or the IV lidocaine to help manage their pain after surgery, and the study will monitor how effective each method is at keeping pain levels down. This research aims to improve pain management strategies for young patients undergoing spinal surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Elective surgery on the thoracic and lumbosacral spine. 2. Signed informed consent to participate in the study; 3. Age 3-17 years.
- Exclusion Criteria:
- • 1. Contraindications to the use of local anesthetics;
- • 2. Operations on the cervical spine;
- • 3. Contraindications to performing ESPB;
- • 4. The patient's refusal to participate in the study.
About Saint Petersburg State University, Russia
Saint Petersburg State University, established in 1724, is a prestigious institution in Russia known for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise to advance medical knowledge and improve patient outcomes through rigorous scientific investigation. With a focus on multidisciplinary collaboration, the university fosters partnerships with healthcare professionals, researchers, and industry stakeholders to conduct high-quality clinical trials that adhere to international standards. Its mission is to contribute to the global healthcare landscape by generating reliable data that informs clinical practices and therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Petersburg, , Russian Federation
Patients applied
Trial Officials
Maxim Sergeevich Monastirniy
Principal Investigator
Saint Petersburg State University, Russia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported